However, when we investigated EPHX4 and ANKRD22 expression in different pathological tumor stages, EPXH4 did not statistically significantly express across cancer stages, F = 1.06, p > 0.05 (Fig. 2C), whereas ANKRD22 showed that its presence between tumor stages was significant with F = 4.8 and p < 0.01. This evidence concerns the gene ANKRD22 and cancer.